Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria von Ochi, Hironori, Hiraoka, Atsushi, Hirooka, Masashi, Koizumi, Yohei, Amano, Michiko, Azemoto, Nobuaki, Watanabe, Takao, Yoshida, Osamu, Tokumoto, Yoshio, Mashiba, Toshie, Yokota, Tomoyuki, Abe, Masanori, Michitaka, Kojiro, Hiasa, Yoichi, Joko, Kouji

Volltext

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis von Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Itobayashi, Ei, Shimada, Noritomo, Tajiri, Kazuto, Tsuji, Kunihiko, Ishikawa, Toru, Ochi, Hironori, Hirooka, Masashi, Tsutsui, Akemi, Shibata, Hiroshi, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro

Volltext

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update von Kudo, Masatoshi, Kawamura, Yusuke, Hasegawa, Kiyoshi, Tateishi, Ryosuke, Kariyama, Kazuya, Shiina, Shuichiro, Toyoda, Hidenori, Imai, Yasuharu, Hiraoka, Atsushi, Ikeda, Masafumi, Izumi, Namiki, Moriguchi, Michihisa, Ogasawara, Sadahisa, Minami, Yasunori, Ueshima, Kazuomi, Murakami, Takamichi, Miyayama, Shiro, Nakashima, Osamu, Yano, Hirohisa, Sakamoto, Michiie, Hatano, Etsuro, Shimada, Mitsuo, Kokudo, Norihiro, Mochida, Satoshi, Takehara, Tetsuo

Volltext

Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma von Koizumi, Yohei, Hirooka, Masashi, Hiraoka, Atsushi, Ochi, Hironori, Tanaka, Takaaki, Yukimoto, Atsushi, Imai, Yuusuke, Watanabe, Takao, Yoshida, Osamu, Miyake, Teruki, Matsuura, Bunzo, Michitaka, Kojiro, Joko, Kouji, Abe, Masanori, Hiasa, Yoichi

Volltext

Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update von Kudo, Masatoshi, Matsui, Osamu, Izumi, Namiki, Kadoya, Masumi, Okusaka, Takuji, Miyayama, Shiro, Yamakado, Koichiro, Tsuchiya, Kaoru, Ueshima, Kazuomi, Hiraoka, Atsushi, Ikeda, Masafumi, Ogasawara, Sadahisa, Yamashita, Tatsuya, Minami, Tetsuya

Volltext

Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC von Kudo, Masatoshi, Kurosaki, Masayuki, Ikeda, Masafumi, Aikata, Hiroshi, Hiraoka, Atsushi, Torimura, Takuji, Sakamoto, Naoya

Volltext

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Ev... von Hiraoka, Atsushi, Michitaka, Kojiro, Kumada, Takashi, Izumi, Namiki, Kadoya, Masumi, Kokudo, Norihiro, Kubo, Shoji, Matsuyama, Yutaka, Nakashima, Osamu, Sakamoto, Michiie, Takayama, Tadatoshi, Kokudo, Takashi, Kashiwabara, Kosuke, Kudo, Masatoshi

Volltext

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan von Kudo, Masatoshi, Matsui, Osamu, Izumi, Namiki, Iijima, Hiroko, Kadoya, Masumi, Imai, Yasuharu, Okusaka, Takuji, Miyayama, Shiro, Tsuchiya, Kaoru, Ueshima, Kazuomi, Hiraoka, Atsushi, Ikeda, Masafumi, Ogasawara, Sadahisa, Yamashita, Tatsuya, Minami, Tetsuya, Yamakado, Koichiro

Volltext

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis von Hiraoka, Atsushi, Kumada, Takashi, Tsuji, Kunihiko, Takaguchi, Koichi, Itobayashi, Ei, Kariyama, Kazuya, Ochi, Hironori, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Ishikawa, Toru, Tachi, Yoshihiko, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi

Volltext

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma von Hiraoka, Atsushi, Kumada, Takashi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Imai, Michitaka, Joko, Kouji, Tanaka, Hironori, Tamai, Tsutomu, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi

Volltext

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis von Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Atsukawa, Masanori, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Shibata, Hiroshi, Ishikawa, Toru, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Itokawa, Norio, Imai, Michitaka, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro

Volltext

Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data von Shimose, Shigeo, Sugimoto, Rie, Hiraoka, Atsushi, Tanaka, Masatoshi, Iwamoto, Hideki, Tanaka, Yuki, Tada, Fujimasa, Ohama, Hideko, Niizeki, Takashi, Shirono, Tomotake, Moriyama, Etsuko, Noda, Yu, Kamachi, Naoki, Nakano, Masahito, Kuromatsu, Ryoko, Koga, Hironori, Kawaguchi, Takumi

Volltext

Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond” von Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Toyoda, Hidenori, Kumada, Takashi

Volltext

Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration... von Ochi, Hironori, Tani, Joji, Tomonari, Tetsu, Taniguchi, Tatsuya, Koizumi, Yohei, Hirose, Akira, Ogawa, Chikara, Hiraoka, Atsushi, Morishita, Akihiro, Moriya, Akio, Hirooka, Masashi, Deguchi, Akihiro, SYMPLE Study Group

Volltext

Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with... von Hatanaka, Takeshi, Hiraoka, Atsushi, Tada, Toshifumi, Kakizaki, Satoru

Volltext

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter... von Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Kumada, Takashi

Volltext

Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease von Kawano, Tadamichi, Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Toyoda, Hidenori, Takaguchi, Koichi, Tani, Joji, Morishita, Asahiro, Hiraoka, Atsushi, Mikami, Shigeru, Ishikawa, Toru, Okubo, Hironao, Watanabe, Tsunamasa, Okubo, Tomomi, Arai, Taeang, Hayama, Korenobu, Itokawa, Norio, Kondo, Chisa, Iwakiri, Katsuhiko

Volltext

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation von Hiraoka, Atsushi, Aibiki, Toshihiko, Okudaira, Tomonari, Toshimori, Akiko, Kawamura, Tomoe, Nakahara, Hiromasa, Suga, Yoshifumi, Azemoto, Nobuaki, Miyata, Hideki, Miyamoto, Yasunao, Ninomiya, Tomoyuki, Hirooka, Masashi, Abe, Masanori, Matsuura, Bunzo, Hiasa, Yoichi, Michitaka, Kojiro

Volltext

Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma von Hiraoka, Atsushi, Kumada, Takashi

Volltext

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis von Hiraoka, Atsushi, Kumada, Takashi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi

Volltext